Genes are the source, growth point and commanding heights of the biopharmaceutical industry. The expansion of technologies derived from genes will be the basis for pharmaceutical companies to develop new products in the 21st century. Genetic research has now become the focus of global attention. Currently, major pharmaceutical, chemical and agricultural companies in the world are actively reorganizing, merging and establishing new alliances to strengthen their competitive strength through gene-related research and development. Although the amount of investment required by the gene industry is very large and the exploration work is also very difficult (for example, it took ten years to isolate the cystic fibrosis gene and cost more than 150 million US dollars), once a gene that can encode a recombinant functional protein is obtained, , the rewards will be extremely generous - the discoverer can obtain the patent of the gene, scientific researchers can conduct relevant research and design relevant prevention and treatment drugs, and pharmaceutical companies can obtain huge market monopoly profits before the patent expires. It can be seen that a gene can build a company and even drive an industry.